Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 5/20 | 0.39 |
| ▸ | CA2 | P00918 | 5/20 | 0.39 |
| ▸ | CA4 | P22748 | 5/20 | 0.39 |
| ▸ | CA12 | O43570 | 4/20 | 0.39 |
| ▸ | CA9 | Q16790 | 4/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL400376 | 0.98 | ALDH1A1 (0.40) | ALDH1A1TSHRCA1CA2CA4 | |
| SCHEMBL5039623 | 0.92 | ALDH1A1 (0.39) | ALDH1A1TSHRCA1CA2CA4 | |
| SCHEMBL22958440 | 0.90 | DGKA (0.41) | ALDH1A1TSHRCA1CA2CA4 | |
| SCHEMBL6029546 | 0.85 | ALDH1A1 (0.34) | ALDH1A1TSHRCA1CA2CA4 | |
| SCHEMBL396155 | 0.82 | CA12 (0.41) | ALDH1A1CA1CA2CA4CA12 | |
| SCHEMBL2010277 | 0.82 | ALDH1A1 (0.52) | ALDH1A1TSHR | |
| SCHEMBL2011728 | 0.82 | ALDH1A1 (0.52) | ALDH1A1TSHR | |
| SCHEMBL2011462 | 0.82 | ALDH1A1 (0.52) | ALDH1A1TSHR | |
| SCHEMBL14894607 | 0.82 | ALDH1A1 (0.52) | ALDH1A1TSHR | |
| SCHEMBL398562 | 0.82 | ALDH1A1 (0.52) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4288413-B1 | PROCESS FOR THE PREPARATION OF A NITRIC OXIDE DONATING PROSTAGLANDIN ANALOGUE | NICOX SA (FR) | 2025-01-22 | — | — | EP | claimed |
| US-20240158345-A1 | PROCESS FOR THE PREPARATION OF A NITRIC OXIDE DONATING PROSTAGLANDIN ANALOGUE | NICOX SA (FR) | 2024-05-16 | — | — | US | claimed |
| EP-4288413-A1 | PROCESS FOR THE PREPARATION OF A NITRIC OXIDE DONATING PROSTAGLANDIN ANALOGUE | Nicox S.A. (FR) | 2023-12-13 | — | — | EP | claimed |
| EP-3772511-B1 | PROCESS FOR THE PREPARATION OF A NITRIC OXIDE DONATING PROSTAGLANDIN ANALOGUE | NICOX SA (FR) | 2023-11-08 | — | — | EP | claimed |
| CN-111757868-B | Nitric oxide donating prostaglandin analogs | 尼科斯股份有限公司 | 2023-03-14 | — | — | CN | claimed |
| US-20220274924-A1 | PROCESS FOR THE PREPARATION OF A NITRIC OXIDE DONATING PROSTAGLANDIN ANALOGUE | NICOX S.A. (FR) | 2022-09-01 | — | — | US | claimed |
| WO-2022167070-A1 | PROCESS FOR THE PREPARATION OF A NITRIC OXIDE DONATING PROSTAGLANDIN ANALOGUE | NICOX S.A. (FR) | 2022-08-11 | — | — | WO | claimed |
| CN-114174261-A | Method for preparing nitric oxide donor type prostaglandin analogue | 尼科斯股份有限公司 | 2022-03-11 | — | — | CN | claimed |
| US-10988438-B2 | Process for the preparation of a nitric oxide donating prostaglandin analogue | NICOX S.A. (FR) | 2021-04-27 | — | — | US | claimed |
| US-20210040032-A1 | PROCESS FOR THE PREPARATION OF A NITRIC OXIDE DONATING PROSTAGLANDIN ANALOGUE | NICOX S.A. (FR) | 2021-02-11 | — | — | US | claimed |
| WO-2021023693-A1 | PROCESS FOR THE PREPARATION OF A NITRIC OXIDE DONATING PROSTAGLANDIN ANALOGUE | NICOX S.A. (FR) | 2021-02-11 | — | — | WO | claimed |
| EP-3772511-A1 | PROCESS FOR THE PREPARATION OF A NITRIC OXIDE DONATING PROSTAGLANDIN ANALOGUE | Nicox S.A. (FR) | 2021-02-10 | — | — | EP | claimed |
| CN-111757868-A | Nitric oxide donating prostaglandin analogs | 尼科斯股份有限公司 | 2020-10-09 | — | — | CN | claimed |
| EP-3530649-B1 | PROCESS FOR THE PREPARATION OF A NITRIC OXIDE DONATING PROSTAGLANDIN ANALOGUE | NICOX SA (FR) | 2020-09-30 | — | — | EP | claimed |
| WO-2019162149-A1 | PROCESS FOR THE PREPARATION OF A NITRIC OXIDE DONATING PROSTAGLANDIN ANALOGUE | NICOX S.A. (FR) | 2019-08-29 | — | — | WO | claimed |
| EP-3530649-A1 | PROCESS FOR THE PREPARATION OF A NITRIC OXIDE DONATING PROSTAGLANDIN ANALOGUE | Nicox S.A. (FR) | 2019-08-28 | — | — | EP | claimed |
| US-20250320182-A1 | INDUSTRIAL PROCESS FOR THE PREPARATION OF HEXANOIC ACID, 6-(NITROOXY)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ETHYLAMINO)-7-OXO-2-HEPTEN-1-YL]-3,5-DIHYDROXYCYCLOPENTYL]-1-(2-PHENYLETHYL)-2-PROPEN-1-YL ESTER AND HIGH PURE PRODUCT | NICOX SA (FR) | 2025-10-16 | — | — | US | disclosed |
| EP-4551553-A1 | INDUSTRIAL PROCESS FOR THE PREPARATION OF HEXANOIC ACID, 6-(NITROOXY)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ETHYLAMINO)-7-OXO-2-HEPTEN-1-YL]-3,5-DIHYDROXYCYCLOPENTYL]-1-(2-PHENYLETHYL)-2-PROPEN-1-YL ESTER AND HIGH PURE PRODUCT | Nicox S.A. (FR) | 2025-05-14 | — | — | EP | disclosed |
| US-7396829-B2 | such as 2H-1,2,4-benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-[5-(nitrooxy)pentyl]-, 1,1-dioxide; contains at least one nitric oxide enhancing group; excessive water or electrolyte retention conditions; cardiovascular diseases, and diseases resulting from oxidative or endothelial dysfunctions | NITROMED, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-7396829-B2 | such as 2H-1,2,4-benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-[5-(nitrooxy)pentyl]-, 1,1-dioxide; contains at least one nitric oxide enhancing group; excessive water or electrolyte retention conditions; cardiovascular diseases, and diseases resulting from oxidative or endothelial dysfunctions | NITROMED, INC. (US) | 2008-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320182-A1 | INDUSTRIAL PROCESS FOR THE PREPARATION OF HEXANOIC ACID, 6-(NITROOXY)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ETHYLAMINO)-7-OXO-2-HEPTEN-1-YL]-3,5-DIHYDROXYCYCLOPENTYL]-1-(2-PHENYLETHYL)-2-PROPEN-1-YL ESTER AND HIGH PURE PRODUCT | CYP2A13, HPD, CYP51A1 | ALDH1A1 503/4885TSHR 790/4885CA1 2860/4885 |
| US-20220274924-A1 | PROCESS FOR THE PREPARATION OF A NITRIC OXIDE DONATING PROSTAGLANDIN ANALOGUE | NOS3, NOS2, NOS1 | ALDH1A1 578/4885TSHR 1950/4885CA1 1202/4885 |
| US-10988438-B2 | Process for the preparation of a nitric oxide donating prostaglandin analogue | NOS3, HPGD, ALOX5 | ALDH1A1 681/4885TSHR 2395/4885CA1 712/4885 |
| US-20210040032-A1 | PROCESS FOR THE PREPARATION OF A NITRIC OXIDE DONATING PROSTAGLANDIN ANALOGUE | NOS3, HPGD, ALOX5 | ALDH1A1 681/4885TSHR 2395/4885CA1 712/4885 |
| US-20240158345-A1 | PROCESS FOR THE PREPARATION OF A NITRIC OXIDE DONATING PROSTAGLANDIN ANALOGUE | NOS3, NOS2, PTGIS | ALDH1A1 625/4885TSHR 1530/4885CA1 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.